

Ichnos Glenmark Innovation (IGI) Appoints Lida Pacaud, M.D., as Interim Chief Executive Officer

NEW YORK, NY, December 03, 2025: Ichnos Glenmark Innovation, Inc. (IGI), a global clinical-stage biotechnology company focused on developing multispecifics™ in oncology, today announced the appointment of Lida Pacaud, M.D., as Interim Chief Executive Officer. She succeeds Cyril Konto, M.D., who has left the company. Dr. Pacaud will report to the IGI Board through its chairman, Glenn Saldanha.

"Lida is an accomplished physician and expert in oncology drug development who has a strong track record of scientific, regulatory and commercial success, having brought multiple novel therapeutics successfully from the clinic to market at leading pharmaceutical companies," **said Glenn Saldanha, Chairman and Managing Director, Glenmark Pharmaceuticals, Ltd.** "Under her leadership, we expect our next-generation immunotherapies based on IGI's BEAT® Multispecific™ platform to continue focusing on meaningful patient outcomes and durable value for our stakeholders."

Dr. Pacaud joined IGI in 2023 as Chief Medical Officer. She played a key role in the clinical development of ISB 2001, a first-in-class trispecific T-cell engager for multiple myeloma that led to the recent global licensing agreement with AbbVie. In addition, Dr. Pacaud brings significant experience in global clinical development strategy, medical affairs, early portfolio planning and collaborations with alliance partners. She has been published as an author on multiple papers in peer-reviewed journals, including New England Journal of Medicine (NEJM), The Lancet Oncology and Journal of Clinical Oncology (JCO). Prior to joining IGI, she served in leadership roles at Legend Biotechnology, Novartis, and Roche, as well as working as a practicing physician earlier in her career.

About IGI

IGI is a global, fully integrated clinical-stage biotechnology company focused on developing innovative biologics in oncology. Headquartered in New York, NY, IGI is advancing a robust pipeline of novel, first-in-class multispecifics™ aimed at addressing complex diseases and treating patients holistically. Powered by its proprietary BEAT® technology platform, IGI is committed to delivering breakthrough curative therapies to improve and extend the lives of patients battling hematological malignancies and solid tumors. For more information, visit www.IGInnovate.com.

IGI Corporate Communications:

Corporate.communications@IGInnovate.com